A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma

Background. The use of statins is a potential protective factor against the development of hepatocellular carcinoma. Therefore, we conducted a meta-analysis to evaluate the contribution of statins to the risk of hepatocellular carcinoma. Methods. We searched for PubMed and EMBASE through January 202...

Full description

Saved in:
Bibliographic Details
Main Authors: Yikai Wang, Wenjun Wang, Muqi Wang, Juanjuan Shi, Xiaoli Jia, Shuangsuo Dang
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2022/5389044
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551230913642496
author Yikai Wang
Wenjun Wang
Muqi Wang
Juanjuan Shi
Xiaoli Jia
Shuangsuo Dang
author_facet Yikai Wang
Wenjun Wang
Muqi Wang
Juanjuan Shi
Xiaoli Jia
Shuangsuo Dang
author_sort Yikai Wang
collection DOAJ
description Background. The use of statins is a potential protective factor against the development of hepatocellular carcinoma. Therefore, we conducted a meta-analysis to evaluate the contribution of statins to the risk of hepatocellular carcinoma. Methods. We searched for PubMed and EMBASE through January 2021. Results. Thirty-two studies (eighteen cohort, eleven case-control, and three randomized controlled trials) reporting 56,838 cases of hepatocellular carcinoma in 4,963,518 persons were included. Statin users were less likely to develop hepatocellular carcinoma than nonusers (adjusted odds ratio, 0.58; 95% CI: 0.51–0.67). Stratified analysis showed that statins reduced the risk of hepatocellular carcinoma in Asian and Western populations (odds ratio, 0.54 vs. 0.60). Besides, statins have protective effects against hepatocellular carcinoma after hepatitis B virus (odds ratio, 0.44; 95% CI: 0.22–0.85) and hepatitis C virus infections (odds ratio, 0.53; 95% CI: 0.49–0.57). Statins have protective effects on people with chronic liver disease (odds ratio, 0.52; 95% CI: 0.40–0.68) and on the general population (odds ratio, 0.60; 95% CI: 0.50–0.72). Lipophilic statins can prevent hepatocellular carcinoma (odds ratio, 0.51, 95% CI: 0.46–0.57), while hydrophilic statins cannot (odds ratio, 0.77, 95% CI: 0.58–1.02). The single-drug analyses showed that simvastatin (odds ratio, 0.53, 95% CI: 0.48–0.59), atorvastatin (odds ratio, 0.54, 95% CI: 0.45–0.64), rosuvastatin (odds ratio, 0.55, 95% CI: 0.37–0.83), lovastatin (odds ratio, 0.30, 95% CI: 0.15–0.62), and pitavastatin (odds ratio, 0.36, 95% CI: 0.17–0.75) had significant benefits. Further studies have shown that those in the high-dose group experienced better effects in preventing hepatocellular carcinoma (adjusted hazard ratio, 0.38 vs. 0.55). Further research found that the combined use of aspirin did not increase the chemoprevention effect of liver cancer (odds ratio, 0.57; 95% CI: 0.40–0.81). In addition, the preventive effect of statins improved with the extension of follow-up time (odds ratio, 0.54 vs. 0.65). Conclusion. Our meta-analysis shows that the use of statins is associated with a lower risk of liver cancer.
format Article
id doaj-art-0838e5490d684ce782e9f22b093b9fb5
institution Kabale University
issn 2291-2797
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-0838e5490d684ce782e9f22b093b9fb52025-02-03T06:01:52ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/5389044A Meta-Analysis of Statin Use and Risk of Hepatocellular CarcinomaYikai Wang0Wenjun Wang1Muqi Wang2Juanjuan Shi3Xiaoli Jia4Shuangsuo Dang5Department of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesBackground. The use of statins is a potential protective factor against the development of hepatocellular carcinoma. Therefore, we conducted a meta-analysis to evaluate the contribution of statins to the risk of hepatocellular carcinoma. Methods. We searched for PubMed and EMBASE through January 2021. Results. Thirty-two studies (eighteen cohort, eleven case-control, and three randomized controlled trials) reporting 56,838 cases of hepatocellular carcinoma in 4,963,518 persons were included. Statin users were less likely to develop hepatocellular carcinoma than nonusers (adjusted odds ratio, 0.58; 95% CI: 0.51–0.67). Stratified analysis showed that statins reduced the risk of hepatocellular carcinoma in Asian and Western populations (odds ratio, 0.54 vs. 0.60). Besides, statins have protective effects against hepatocellular carcinoma after hepatitis B virus (odds ratio, 0.44; 95% CI: 0.22–0.85) and hepatitis C virus infections (odds ratio, 0.53; 95% CI: 0.49–0.57). Statins have protective effects on people with chronic liver disease (odds ratio, 0.52; 95% CI: 0.40–0.68) and on the general population (odds ratio, 0.60; 95% CI: 0.50–0.72). Lipophilic statins can prevent hepatocellular carcinoma (odds ratio, 0.51, 95% CI: 0.46–0.57), while hydrophilic statins cannot (odds ratio, 0.77, 95% CI: 0.58–1.02). The single-drug analyses showed that simvastatin (odds ratio, 0.53, 95% CI: 0.48–0.59), atorvastatin (odds ratio, 0.54, 95% CI: 0.45–0.64), rosuvastatin (odds ratio, 0.55, 95% CI: 0.37–0.83), lovastatin (odds ratio, 0.30, 95% CI: 0.15–0.62), and pitavastatin (odds ratio, 0.36, 95% CI: 0.17–0.75) had significant benefits. Further studies have shown that those in the high-dose group experienced better effects in preventing hepatocellular carcinoma (adjusted hazard ratio, 0.38 vs. 0.55). Further research found that the combined use of aspirin did not increase the chemoprevention effect of liver cancer (odds ratio, 0.57; 95% CI: 0.40–0.81). In addition, the preventive effect of statins improved with the extension of follow-up time (odds ratio, 0.54 vs. 0.65). Conclusion. Our meta-analysis shows that the use of statins is associated with a lower risk of liver cancer.http://dx.doi.org/10.1155/2022/5389044
spellingShingle Yikai Wang
Wenjun Wang
Muqi Wang
Juanjuan Shi
Xiaoli Jia
Shuangsuo Dang
A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
Canadian Journal of Gastroenterology and Hepatology
title A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
title_full A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
title_fullStr A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
title_full_unstemmed A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
title_short A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma
title_sort meta analysis of statin use and risk of hepatocellular carcinoma
url http://dx.doi.org/10.1155/2022/5389044
work_keys_str_mv AT yikaiwang ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT wenjunwang ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT muqiwang ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT juanjuanshi ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT xiaolijia ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT shuangsuodang ametaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT yikaiwang metaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT wenjunwang metaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT muqiwang metaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT juanjuanshi metaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT xiaolijia metaanalysisofstatinuseandriskofhepatocellularcarcinoma
AT shuangsuodang metaanalysisofstatinuseandriskofhepatocellularcarcinoma